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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYLittle is known about the extracellular signaling factors that govern mammary stem cell behavior. Here, we identify CRIPTO and its cell-
surface receptor GRP78 as regulators of stem cell behavior in isolated fetal and adult mammary epithelial cells. We develop a CRIPTO
antagonist that promotes differentiation and reduces self-renewal of mammary stem cell-enriched populations cultured ex vivo.
By contrast, CRIPTO treatment maintains the stem cell phenotype in these cultures and yields colonies with enhanced mammary gland
reconstitution capacity. Surface expression of GRP78 marks CRIPTO-responsive, stem cell-enriched fetal and adult mammary epithelial
cells, and deletion of GRP78 from adult mammary epithelial cells blocks their mammary gland reconstitution potential. Together, these
findings identify the CRIPTO/GRP78 pathway as a developmentally conserved regulator of fetal and adult mammary stem cell behavior
ex vivo, with implications for the stem-like cells found in many cancers.INTRODUCTION
Somatic stem cells govern the development, mainte-
nance, and regeneration of tissues, and their dysregu-
lation is associated with diverse pathologies, including
cancer. Given the significance of these cells both biologi-
cally and therapeutically, it is critical to define factors
and signaling mechanisms that dictate their behavior,
including those that define niches capable of promoting
the stem cell phenotype in normal and disease settings.
However, few such factors have been elucidated, and
progress toward this goal has been impeded by the fact
that most somatic stem cells, including those of the mam-
mary gland, are rare and difficult to isolate and propagate
ex vivo.
The mammary epithelium consists principally of line-
age-restricted basal keratin-14-positive (KRT14+) myo-
epithelial cells and keratin-8-positive (KRT8+) luminal
epithelial cells (Mikaelian et al., 2006). Although recent
reports indicate extensive self-renewal within each of
these lineage-committed populations (Van Keymeulen
et al., 2011), classic single-cell transplant experiments
indicate the presence of rare transplantable bipotent
mammary stem cells (MaSCs) in the mature mammary
gland (Shackleton et al., 2006). These cells can be signifi-
cantly enriched through the use of cell-surface marker
combinations such as CD24 and CD49f (Stingl et al.,
2006). However, the functional significance of such
markers to stem cell biology is often unclear, and the re-Stemsulting enrichment generally remains too low to discern
core molecular determinants of the stem cell state from
the population at large.
In an effort to circumvent these challenges, we recently
characterized a highly enriched population of stem
cells from murine embryonic mammary rudiments (Spike
et al., 2012). The greater purity of these fetal mammary
stem cells (fMaSC) relative to their adult counterparts
makes them particularly useful in the study of MaSC
biology. Interestingly, we found that fMaSCs share gene
expression features with certain aggressive human breast
cancers that are not shared between enriched populations
of adult MaSCs and the same breast cancers. This distinc-
tion may reflect intrinsic differences between the fetal
and adult MaSCs or differential heterogeneity in the stem
cell-enriched populations used for profiling. Alternatively,
this observation may be due to critical differences in
the tissue contexts from which these cells are derived, a
possibility consistent with prior reports indicating an
important role for microenvironmental factors in estab-
lishing and maintaining the stem cell competence of
both fetal and adult mammary cells (Makarem et al.,
2013; Spike et al., 2012; Vaillant et al., 2011). However,
the ability of specific factors to promote the MaSC pheno-
type has rarely been directly demonstrated.
CRIPTO (CR-1, TDGF1) is an oncofetal, GPI-anchored/
secreted signaling protein that plays key roles as a stem
cell regulator (Adewumi et al., 2007; Bianco et al., 2010;
Hough et al., 2009; Miharada et al., 2011). CRIPTO isCell Reports j Vol. 2 j 427–439 j April 8, 2014 j ª2014 The Authors 427
Figure 1. ALK4L75A-Fc Inhibits Growth-Factor-like Effects of CRIPTO on Immortalized Human Mammary Epithelial Cells
(A) ALK4L75A-Fc (10 mg/ml) inhibits binding of 125I-CRIPTO to native MCF10A cells. Data from one of two independent experiments using
three technical replicates are shown, with SDs.
(B) Phospho-AKT (Ser 473) or total AKT western blots on lysates from MCF10A cells treated with soluble CRIPTO (300 ng/ml), ALK4L75A-Fc,
and PI3K inhibitor LY 294002 (10 mM) as indicated.
(legend continued on next page)
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CRIPTO and GRP78 Regulate Mammary Stem Cellsdynamically expressed during mammary gland develop-
ment (Bianco et al., 2008; Kenney et al., 1995) and in breast
cancer (Gong et al., 2007) but has not been previously
examined in the context of MaSCs. CRIPTO promotes
proliferation, invasion, and migration of mammary epi-
thelial cell lines in vitro, whereas its overexpression in
the mouse mammary gland promotes excessive ductal
branching, hyperplasia, and latent tumor growth (Rangel
et al., 2012). Although the relevant molecular and cellular
mechanisms for these effects remain to be determined,
CRIPTO impacts multiple signaling pathways associated
with stem cells and oncogenesis, including transforming
growth factor b (TGF-b), phosphatidylinositol 3-kinase
(PI3K), WNT, and NOTCH (Rangel et al., 2012). Two
distinct CRIPTO signaling activities have been best charac-
terized: (1) a coreceptor function in which CRIPTO modu-
lates signaling of TGF-b ligands such as NODAL that signal
via SMAD2/3 activation and (2) a growth-factor-like acti-
vity in which soluble CRIPTO activates SRC/mitogen-acti-
vated protein kinase/PI3K pathways in a TGF-b pathway-
independent manner (Bianco et al., 2002; Gray and Vale,
2012). Both of these signaling activities require CRIPTO
binding to cell-surface GRP78, an HSP70 family member
that localizes to the surfaces of stem cells and tumor cells
(Gray and Vale, 2012; Kelber et al., 2009; Miharada et al.,
2011; Shani et al., 2008).
Here, we investigate CRIPTO’s ability to regulate primary
fetal and adult mammary stem/progenitor cells using a se-
ries of ex vivo culture and mammary gland reconstitution
experiments. We develop an antagonist that selectively
blocks the growth factor-like signaling of soluble CRIPTO
without affecting its cell-surface coreceptor activity, and
we use this reagent to demonstrate that soluble CRIPTO
maintains the MaSC state ex vivo. We further identify
cell-surface GRP78 as a determinant of CRIPTO respon-
siveness and critical functional marker in fetal and adult
MaSCs.(C) Phospho-SMAD2 and SMAD2/3 western blots on MCF10A cells stab
(MCF10A-V) and treated as indicated with ACTIVIN A (1 nM), NODAL (3
(D) Time course showing that MCF10A-CR cells accumulate more rapi
selectively inhibits growth of MCF10A-CR cells. *p < 0.01. Triplicate
(E) MCF10A-CR cells are more migratory than MCF10A-V cells. The CRI
blocked by ALK4L75A-Fc treatment or a GRP78 neutralizing antibody (N
from three fields of view per condition in one experiment (of two pe
(F) Suspension cultures of MCF10A-V and MCF10A-CR cells 11 days afte
MCF10A-V cells in suspension culture, and this growth advantage is i
(G) MCF10A-CR cells produce larger and more plentiful colonies th
suspension cultures, and ALK4L75A-Fc treatment blocks this CRIPTO-d
(H) Colony growth was significantly reduced by either ALK4L75A-Fc tre
with SB 431542. *p < 0.05. Two independent experiments with dup
increased colony number, but not mean size, of MCF10A-V cells.
See also Figures S1 and S2.
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An ALK4-Based Antagonist Inhibits Growth-Factor-
like Effects of Soluble CRIPTO on Mammary
Epithelial Cells
We developed a CRIPTO antagonist in order to test
if CRIPTO signaling is required for the maintenance of
MaSCs. We took advantage of the CRIPTO binding proper-
ties of the extracellular domain (ECD) of the ACTIVIN/
NODAL type I receptor ALK4 (Bianco et al., 2002; Gray
and Vale, 2012; Yeo and Whitman, 2001) and the fact
that a leucine to alanine substitution at amino acid 75
(L75A) disrupts ALK4/ACTIVIN binding without affecting
ALK4 binding to CRIPTO (Kelber et al., 2008). Although
the L75Amutation does not guarantee complete specificity
of ALK4 ECD binding to CRIPTO, we reasoned that
this substitution should increase the selectivity of their
interaction. We previously showed that a kinase-deleted
ALK4L75A protein blocks CRIPTO effects on ACTIVIN and
NODAL signaling (Kelber et al., 2008), leading us to
hypothesize that a soluble version of the ALK4L75A ECD
would similarly block CRIPTO signaling. To test this, we
fused an N-terminally Flag-tagged ALK4-ECDL75A to the
Fc region of human immunoglobulin G (ALK4L75A-Fc).
We purified the recombinant protein from conditioned
media using affinity chromatography and confirmed its
ability to bind CRIPTO in solution (Figures S1A–S1D and
Supplemental Experimental Procedures available online).
Using the CRIPTO-responsive human mammary epithe-
lial MCF10A cell line, we find that ALK4L75A-Fc effectively
inhibits binding of soluble CRIPTO to intact cells and
blocks CRIPTO-dependent augmentation of AKT phos-
phorylation (Figures 1A and 1B). This effect appears to be
specific, because ALK4L75A-Fc only blocks CRIPTO-depen-
dent AKT phosphorylation, whereas a PI3K inhibitor
(LY 294002) blocks detection of both CRIPTO-induced
and basal phospho-AKT (Figure 1B). As expected, and inly transduced with CRIPTO-Flag virus (MCF10A-CR) or control virus
0 nM), ALK4L75A-Fc, and the ALK4/5/7 inhibitor SB 431542 (10 mM).
dly than MCF10A-V cells in 2D culture. Treatment with ALK4L75A-Fc
wells in a representative experiment are shown, with SDs.
PTO-dependent increase in migrational velocity and persistence is
-20). **p < 0.01, two-way ANOVA. Data fromR50 individual cells
rformed) are shown, with SDs.
r seeding in 24-well plates. MCF10A-CR cells grow more rapidly than
nhibited by ALK4L75A-Fc treatment.
an MCF10A-V cells when grown in immobilizing methylcellulose
ependent growth. Bar represents 30 mm.
atment or PI3K inhibition (LY 294002 10 mM), but not by treatment
licate wells in each are tabulated, with SDs. SB 431542 treatment
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NODAL treatment induces SMAD2 phosphorylation in
MCF10A cells stably transduced with CRIPTO lentivirus
(MCF10A-CR), but not in control cells transduced with
empty vector (MCF10A-V) (Figure 1C). Both NODAL and
ACTIVIN A signal via ALK4, and SMAD2 phosphorylation
in response to each ligand is blocked by the ALK4/5/7
kinase inhibitor SB 431542 (Figure 1C). ALK4L75A-Fc
treatment, on the other hand, has no effect on ACTIVIN
A-induced SMAD2phosphorylation (Figure 1C), consistent
with our previous demonstration that the ALK4L75A
mutation blocks ACTIVIN A binding (Kelber et al., 2008).
Surprisingly, however, ALK4L75A-Fc treatment also has
no discernible effect on CRIPTO-dependent NODAL
signaling in MCF10A-CR cells (Figure 1C) or on CRIPTO-
dependent NODAL induction of a SMAD2-responsive
luciferase reporter in 293T cells (Figure S1E). This failure
of ALK4L75A-Fc to block CRIPTO coreceptor activity is
consistent with our inability to detect ALK4L75A-Fc binding
on the surface of intact CRIPTO-overexpressing 293T cells
(Figure S1F).
MCF10A-CR cells secrete CRIPTO (Figure S2A) and have
elevated levels of PI3K/AKT signaling relative to MCF10A-
V cells (Figure S2B), leading us to test if ALK4L75A-Fc
inhibits autocrine/paracrine CRIPTO growth factor activity
in these cells. We use live-cell time-course and time-lapse
microscopy, respectively, to track proliferation and migra-
tion of MCF10A-CR cells and control cells (MCF10A-V).
MCF10A-CR cells accumulate more rapidly than MCF10A-
V cells (Figure 1D), consistent with our previous findings
(Kelber et al., 2009), and these CRIPTO expressing cells
also have enhanced migration relative to control cells
(Figure 1E). Treatment with ALK4L75A-Fc inhibits the
CRIPTO-dependent increases in growth (Figure 1D) and
motility (Figure 1E; Figure S2C; Movies S1, S2, S3, and
S4). The inhibitory effects of ALK4L75A-Fc treatment on
CRIPTO-dependent migrational velocity and persistence
are similar to those of GRP78 antibody (N-20) (Figure 1E;
Figure S2C) that we previously showed blocks CRIPTO/
GRP78 binding (Kelber et al., 2009).
We also analyzed the effects of CRIPTO signaling and
antagonism onMCF10A cells in 3D culture in the presence
or absence of the reconstituted basement membrane
Matrigel. Although suspension cultures have been widely
used to measure the production of multicellular mammary
epithelial structures called ‘‘mammospheres’’ (Dontu et al.,
2003), Matrigel-containing mammary epithelial cultures
promote the formation of differentiated, polarized acinar
structures from MCF10A cells and multilayered, multi-
lineage organoids from primary mammary epithelial stem
cells (Debnath et al., 2003; Spike et al., 2012). MCF10A-
CR cells accumulate more rapidly than MCF10A-V cells
in free-floating suspension cultures, where they exhibit430 Stem Cell Reports j Vol. 2 j 427–439 j April 8, 2014 j ª2014 The Authora greater proportion of cells with 2N-4N DNA content
indicative of cycling S phase cells (Figure 1F; Figures S2D
and S2E). The growth promoting effects of CRIPTO under
these conditions are blocked by treatment with ALK4L75A-
Fc or LY 294002, but not SB 431542 (Figure S2D). We
usedmethylcellulose immobilization of cells in suspension
cultures to measure the size of individual spheres (Figures
1G and 1H). Consistent with the increased cell numbers
observed in free-floating cultures, immobilized MCF10A-
CR cells form larger, more numerous mammospheres
than MCF10A-V cells, and the increased growth of the
CRIPTO-expressing cells is again blocked by ALK4L75A-Fc
and LY 294002, but not by SB 431542 (Figure 1H). CRIPTO
overexpression similarly promotesMCF10A colony growth
in Matrigel, and this is inhibited by treatment with
ALK4L75A-Fc, whereas treatment of these cultures with
NODAL neither augments CRIPTO-induced growth nor
overcomes ALK4L75A-Fc -mediated inhibition of CRIPTO-
induced growth (Figure S2F). Altogether, these results
indicate that soluble CRIPTO promotes proliferation and
migration of mammary epithelial cells and that this can
be blocked by ALK4L75A-Fc.
CRIPTO/GRP78 Expression and Function in fMaSCs
Our data show that MCF10A cells respond to soluble
CRIPTO signaling in multiple contexts, including 3D
growth assays that are similar to those used previously to
evaluate stem cell-like cellular behaviors (Dontu et al.,
2003). We also previously demonstrated that soluble
CRIPTO activates the PI3K/AKT pathway in MCF10A cells
by binding to cell-surface GRP78 (Kelber et al., 2009). These
findings, together with reports that CRIPTO and GRP78
cooperatively regulate stem cell function in other contexts,
prompted us to test if CRIPTO and GRP78 are expressed
in murine mammary tissue and if the CRIPTO/GRP78
pathway is operative in primary mammary stem/progeni-
tor cells. We first investigated the pattern of CRIPTO
and GRP78 expression in embryonic day 18.5 (E18.5)
mouse mammary rudiments, because they provide a rich
source of robust stem cell activity (Spike et al., 2012). We
find GRP78 to be expressed throughout the mammary
rudiment, with the most intense and distinct staining
coinciding with the burgeoning, arborized mammary
epithelium, demarcated here by costaining with antibodies
to KRT8 (Figures 2A and 2B). By contrast, CRIPTO staining
is more diffuse and distributed throughout the rudiment,
with significant staining in the fetal mammary stroma
and areas within and adjacent to the GRP78-positive
and KRT8-positive epithelium. Interestingly, we observe
intense CRIPTO staining at or near the termini of the
arborized mammary rudiment, where it overlaps with
both the condensed mesenchyme adjacent to the epi-
thelium and epithelial cells that stain prominently fors
Figure 2. Expression of CRIPTO and GRP78 in the Fetal Mammary Rudiment and Responsiveness of fMaSCs to Soluble CRIPTO
(A and B) Whole-mount E18.5 fetal mammary rudiment demarcated with immunofluorescence staining for KRT8 (blue) or DAPI (white) and
costained for CRIPTO (green) and GRP78 (red) (right). (A, i–iii) control rudiment stained with KRT8 and isotype-matched controls for
GRP78 and CRIPTO. Scale bar represents 200 mm (A) or 50 mm (B).
(C) CRIPTO is expressed in the fMaSC population and stromal cells as measured by RT-PCR. A total of 150 rudiments were pooled and assayed
in technical triplicates, with SDs.
(D) CRIPTO staining colocalizes with F4/80 staining (arrows) adjacent to mammary epithelium demarcated by KRT8 staining (blue).
(E) Flow cytometric analysis of fetal mouse mammary cells stained with CD24, GRP78, and isotype control antibodies as indicated. The
percentage of the CD24high population also positive for GRP78 is shown.
(F) Phospho-AKT staining in serum-starved, fMaSC-derived organoids treated as indicated with soluble CRIPTO (300 ng/ml), ALK4L75A-Fc
(10 mg/ml), LY 294002 (10 mM), or N-20 (2 mg/ml). Scale bar represents 50 mm.
(G) 2D fMaSC cultures were treated with CRIPTO (400 ng/ml) and/or ALK4L75A-Fc (10 mg/ml) as indicated and stained with Ki67 antibody
and DAPI. Scale bar represents 50 mm, and inset represents 10 mm.
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in fMaSCs but is more highly expressed in a variety of
other cell populations isolated from the fetal mammary
microenvironment, including putative adipose precursor
cells that resist centrifugation during rudiment process-
ing (‘‘Fat’’), myeloid cells (Lin+CD11b+F4/80+), and non-
myeloid lineage-positive cells (CD11bF4/80) (Figure 2C).
CRIPTO message is also present in other stromal cells
(fStromal; LinCD24low) that likely include mammaryStemtissue fibroblasts (Figure 2C). Costaining of the mammary
rudiment for the macrophage marker F4/80 confirms
colocalization of CRIPTO protein with not only macro-
phages but also other nonmacrophage stromal compo-
nents adjacent to the fetal mammary epithelium (Fig-
ure 2D). Thus, CRIPTO is expressed in multiple cell types
within the MaSC microenvironment, leading us to reason
that soluble secreted CRIPTO may govern fMaSC behavior
as an autocrine/paracrine growth factor.Cell Reports j Vol. 2 j 427–439 j April 8, 2014 j ª2014 The Authors 431
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CRIPTO and GRP78 Regulate Mammary Stem CellsOur previous studies indicating that CRIPTO signals
via cell-surface GRP78 led us to test if GRP78 is expressed
on the surface of fMaSCs (LinCD24high) and if these
cells respond to soluble CRIPTO in a GRP78-dependent
manner. We analyzed dissociated cells from E18.5 mam-
mary rudiments by flow cytometry and discovered that
>80% of the fMaSC population is GRP78 positive (Fig-
ure 2E). Furthermore, when we treat fMaSC-derived
Matrigel colonies with soluble CRIPTO, we observe
increased AKT phosphorylation that is blocked by treat-
ment with ALK4L75A-Fc or LY 294002 (Figure 2F). This
increase in AKT phosphorylation is also blocked by N-20,
indicating that CRIPTO signals via cell-surface GRP78
in these cells (Figure 2F). Soluble CRIPTO treatment
also increases the proportion of Ki67+ cells relative to
untreated cells in 2D culture, and this effect was once again
blocked by ALK4L75A-Fc treatment (Figure 2G). Thus,
multiple cell types within the fetal mammary rudiment
produce CRIPTO, and it can act on cells within the fMaSC
population.
CRIPTO/GRP78 Signaling Promotes Maintenance
of fMaSCs Ex Vivo
To explore the consequences of CRIPTO signaling in
MaSCs further, we examined its effects on growth, self-
renewal, and differentiation in fMaSC cultures. We pre-
viously reported that fMaSCs grown in media that pro-
motes their differentiation give rise to a high proportion
of bilineage organoids containing both KRT8+KRT14
luminal cells and KRT14+KRT8 myoepithelial cells by
7–12 days of culture (Spike et al., 2012). At 5 days of culture,
organoids grown in this differentiation promoting media
typically contain a fraction of cells coexpressing KRT8
and KRT14 (Figure 3A, top left, yellow arrows, and Fig-
ure 3B). Supplementation of these cultures with CRIPTO
or ALK4L75A-Fc has opposing effects on the fraction of
organoids containing double-positive (KRT8+KRT14+) cells
and on the amount of double-positive area per organoid
(Figure 3A, left panels, and Figure 3B; Figures S3A and
S3B). Specifically, CRIPTO treatment increases the propor-
tion of double-positive area per organoid while ALK4L75A-
Fc treatment decreases it, suggesting that CRIPTO signaling
promotes maintenance of a multipotent phenotype.
However, rapid cellular differentiation under these culture
conditions prevented us from confirming stem cell activity
of resultant colonies by mammary reconstitution analyses
(data not shown; Spike et al., 2012).
To address this issue, we developed culture conditions
that are better able to produce mammary epithelial col-
onies including bilineage organoids that also give rise to
mammary outgrowths following transplantation. CRIPTO
and ALK4L75A-Fc also have opposite effects on the stem
cell phenotype of fMaSC-derived colonies grown in this432 Stem Cell Reports j Vol. 2 j 427–439 j April 8, 2014 j ª2014 The Authorstem cell maintenance media (Figure 3A, right panels,
and Figure 3B). Endogenous CRIPTO is implicated as
a stem cell factor in these cultures by the fact that
ALK4L75A-Fc treatment alone increases the number of kera-
tin single-positive cells discernible per organoid (Figure 3A,
right panels, red arrows). ALK4L75A-Fc also significantly
increases the amount of single keratin staining area (either
KRT14+KRT8 or KRT8+KRT14) relative to KRT8+KRT14+
double-positive area per organoid (Figure 3B; Figure S3B),
although some double-positive cells are evident in all
organoids in maintenance media following 5 days of
culture (Figures 3A and 3B; Figure S3B).
Although our data indicate that CRIPTO signaling corre-
lates with KRT8+KRT14+ double positivity, the precise
relationship between keratin expression and differentia-
tion status in these cultures is uncertain. It is therefore
important that CRIPTO signaling also has functional stem
cell relevance, because treatment with soluble CRIPTO
enhanced the ability of fMaSC-derived colonies grown for
5 days in this media to reconstitute mammary glands
upon transplantation relative to untreated controls
and this CRIPTO effect was attenuated by ALK4L75A-Fc
(Figure 3C). Despite the clear effects of CRIPTO signaling
on keratin expression and transplantation, treatment
with CRIPTO and/or ALK4L75A-Fc does not significantly
affect overall colony number and size in 5-day cultures
(Figure 3D). However, when cells are serially passaged for
three rounds under stem cell maintenance conditions,
ALK4L75A-Fc treatment substantially reduces colony-form-
ing efficiency and the growth of large colonies (>100 mm)
is almost completely abolished (Figure 3D). Conversely,
addition of CRIPTO can support a round of serial passage
of fMaSC-derived cells, even under conditions that
strongly favor differentiation (Figure 3D). We note that
clonogenicity of fetal mammary cells was recently shown
to be enhanced by unidentified factors secreted by 3T3
fibroblasts in coculture (Makarem et al., 2013). We find
that 3T3 cells express CRIPTO protein (Figure S3D) and
that their ability to enhance clonogenicity of fetal
mammary cells in coculture can be partially blocked by
treatment with either ALK4L75A-Fc or CRIPTO antibodies
(Figure S3E). This result is consistent with our results using
recombinant proteins and further highlights the potential
for non-cell-autonomous CRIPTO regulation of fMaSCs.
GRP78 Is a Critical FunctionalMarker andCell-Surface
Determinant of CRIPTO-Responsive MaSCs
We examined CRIPTO and GRP78 expression in the adult
mammary gland and identified marked immunoreactivity
for both proteins that overlaps with the morphologically
distinct mammary ductal epithelium and adjacent adipose
tissue (Figure 4A). Immunofluorescent colocalization
studies confirm overlapping CRIPTO and GRP78 stainings
Figure 3. CRIPTO Promotes Maintenance of fMaSCs
(A) Sphere-bisecting confocal cross sections of day 5, fMaSC-derived colonies grown in Matrigel and stained with KRT8 (green) and KRT14
(red). Colonies were grown in differentiation media or maintenance media with soluble CRIPTO (0.33 mg/ml) or ALK4L75A-Fc (10 mg/ml) as
indicated. Yellow arrows indicate KRT8+KRT14+ double-positive cells. Red arrows indicate lineage-committed KRT14 single-positive cells.
Control represents the same isotype. Scale bar represents 100 mm.
(B) KRT8 and KRT14 staining was quantified from images and is represented as the percent KRT8+KRT14+ double-labeled area per organoid.
The percentage of organoids containing KRT8+KRT14+ double-labeled cells is also indicated. Results of three independent representative
experiments are shown.
(C) Mammary gland repopulation efficiency of first-generation colonies grown in Matrigel-containing maintenance media culture with
soluble CRIPTO and/or ALK4L75A-Fc. Each circle represents one recipient mammary gland. Shaded circles represent ducts extending
through >50% of the fat pad.
(D) Colony-forming efficiencies (>100 mm) at first, second, and third passage for fMaSCs grown for 7 days per passage in differentiation
or maintenance media with CRIPTO and/or ALK4L75A-Fc. Results of three independent experiments (maintenance media) and a repre-
sentative experiment (differentiation media) were quantified. Triplicate wells were quantified in each. Error bars represent SDs. *p% 0.01.
See also Figure S3.
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and a subset of mammary epithelial cells (Figure 4B). To
determine whether adult MaSCs require GRP78, we used
CRE-mediated recombination and excision of GRP78
alleles together withmammary gland reconstitution exper-
iments. In these experiments, cells harboring CRE-express-
ing virus failed to reconstitute mammary ductal trees in
each of nine transplant attempts (zero out of nine), whileSteman equivalent number of cells transduced with control
virus robustly repopulate the gland (three out of three)
(Figure 4A). Furthermore, cells isolated from control out-
growths exhibit cell-surface GRP78 and contain both the
luminal and myoepithelial fractions (Figure S4C). In
contrast, we only occasionally recover a low number of
presumptive mammary epithelial cells from transplants
of GRP78Fl/Fl cells infected with CRE virus. These cellsCell Reports j Vol. 2 j 427–439 j April 8, 2014 j ª2014 The Authors 433
Figure 4. GRP78 Is Required for MaSC Activity and Marks a CRIPTO-Responsive Stem Cell-Enriched Population of Adult Mouse
Mammary Epithelial Cells
(A) Immunohistochemical localization of CRIPTO and GRP78 in adult mouse mammary tissue. Inset: secondary antibody alone (2nd).
(B) CRIPTO and GRP78 proteins colocalize in stromal areas including adipose (f, fat) and in epithelial structures (e), where a subset of cells
display elevated staining for both markers (white arrows).
(C) Repopulation rate of de-epithelialized mammary glands inoculated with 500 GRP78-floxed epithelial cells transduced with Ad-CRE/
GFP- or Ad-GFP and sorted for GFP. Each circle represents one recipient mammary gland. Filled circles indicate >50% fat pad filling.
(D) Flow cytometric analysis of wild-type adult mouse mammary cells stained for CD24 and GRP78 (lineage excluded) indicating the
presence of cell-surface GRP78 in adult mammary epithelia and demarcating the GRP78high and GRP78low populations (left). Antibodies to
CD49f were also incorporated (right), and cells positive for GRP78 and CD24 were gated to generate a population density graph (red lines)
superimposed on the CD24/CD49f staining. The standard positions of the CFC, MYO, and MRU populations (Stingl et al., 2006) are indi-
cated.
(E) Colonies grown from single cells sorted into individual wells in 96-well plates. Luminal, organoid, and myoepithelial morphologies were
distinguishable (left). The number of each type of clonal outgrowth deriving from single GRP78low and GRP78high cells in one represen-
tative experiment (of three similar experiments) was quantified according to morphology (right).
(F) Confocal micrographs showing the keratin distribution observed in representative colonies grown from cells sorted using CD24 and
GRP78. GRP78low cells predominantly expressed either KRT8 or KRT14, while GRP78high cultures frequently exhibited KRT8+KRT14+ out-
growths. Representative organoid (i), luminal (ii), and myoepithelial (iii) colonies are shown. Color panels show individual fluorophores
separately for the organoid (i, insets). Scale bars represent 100 mm.
(legend continued on next page)
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CRIPTO and GRP78 Regulate Mammary Stem Cellsappear restricted to the mature luminal fraction, lack
detectable cell-surface GRP78, and do not give rise to col-
onies when cultured in vitro (Figure S4A; data not shown).
These data indicate that GRP78 is required for MaSC acti-
vity as measured by transplantation assays.
Next, we sought to examine the role of cell-surface
GRP78 as an adult MaSC marker and as a MaSC regulator
specifically in its capacity as a mediator of CRIPTO sig-
naling. We isolated CD24-positive mammary epithelial
cells with either high (GRP78high) or low (GRP78low) levels
of cell-surface GRP78 from wild-type mice (Figure 4D, left
panel). A substantial portion of adult mammary epithelial
cells was GRP78high (19.4% ± 3.4% of the CD24-positive
fraction), though the proportion was considerably lower
than in fetal mammary epithelia (Figure 3D). In costained
samples, we observe that while the GRP78high population
overlaps partially with the previously reported luminal
colony-forming cell (CFC) andmyoepithelial (MYO) popu-
lations, it overlaps most precisely with the stem cell-
enriched CD24medCD49fhigh mammary repopulating unit
(MRU) fraction (Figure 4D, right panel) (Stingl et al.,
2006). While cells from both the GRP78high and GRP78low
fractions produce clonal outgrowths in Matrigel culture,
those derived from the GRP78high population are much
more likely to give rise to colonies containing multiple
cell layers (Figure 4E; organoids) and to stain positive for
both KRT14 and KRT8 (Figure 4F; Figure S4B). In these as-
says, the most frequently observed and morphologically
distinguishable colony types include those that appear
luminal, composed of a single peripheral cell layer sur-
rounding an open lumen, small myoepithelial colonies
(usually < 16 cells), and distinctive, multilayered organoids
containing both luminal and myoepithelial cell types
(Figures 4E and 4F) (Spike et al., 2012; Stingl et al., 2006).
Importantly, these morphologically distinct colony types
are produced in cultures both when single cells were plated
in individual wells (Figure 4E) and when cells are plated at
single-cell densities (1,000 cells per 0.32 cm2) (Figure 4F;
data not shown) (Spike et al., 2012). Thus, the substantially
higher proportion of organoids and KRT14+KRT8+ double-
positive colonies formed from the GRP78high population
(Figures 4E and 4F; Figure S4B) suggests that the GRP78high
population is enriched for bipotent stem/progenitor
cells. In contrast, GRP78low cells predominantly give rise(G) Mammary gland repopulation efficiencies of GRP78high and GRP
likelihood ratio test p = 0.938; ELDA).
(H) GRP78high cells are selectively responsive to soluble CRIPTO or A
Results of two independent experiments conducted in triplicate are s
(I) Model depicting cooperativity of soluble CRIPTO (sCR) and ce
Soluble CRIPTO reinforces a robust primitive epithelial stem cell stat
to differentiation cues and eventual loss of stem cell characteristics
See also Figure S4.
Stemto small myoepithelial (KRT14+KRT8) or monolayered
luminal (KRT14KRT8+) outgrowths (Figures 4E and 4F;
Figure S4B).
As an independent criterion for assessing the stem cell
content of the GRP78high population, we transplanted
CD24medGRP78high and CD24medGRP78low mammary
epithelial cell populations into cleared mammary fat
pads at limiting dilutions. The results clearly indicate that
the CD24medGRP78high cells reconstitute mammary glands
more efficiently the CD24medGRP78low cells (Figure 4G;
Figures S4C–S4E). We estimate the frequency of mammary
gland-reconstituting units to be approximately 1/26 in
the GRP78high cells (90% confidence interval [CI], 1/15–
45.4; extreme limiting dilution analysis [ELDA]) versus
approximately 1/152 in the GRP78low population (90%
CI, 1/67.0–346.2; ELDA) (Figure 4G; Figure S4E). This corre-
lates with a significant enrichment (p < 0.01; ELDA) of
stem cell activity in the GRP78high fraction relative to the
GRP78low cells (Figure 4G; Figures S4C–S4E). Outgrowths
from transplanted GRP78high cells resemble endogenous
mammary glands in FACS analyses including the presence
of GRP78high cells within the CD24 expressing mammary
epithelium (Figure S4F). Significantly, the self-renewal
potential of these cells is evident in their capacity to recon-
stitute fully arborized mammary epithelial outgrowths in
tertiary transplants that respond normally to pregnancy
(Figure S4G). We also identify a diffuse, small, and variable
population of GRP78 ‘‘superpositive’’ (GRP78high+) cells
with intermediate performance in stem cell assays (Figures
S4D and S4E).
Because CRIPTO signaling promotes serial passage of
fMaSCs ex vivo (Figure 3D), we tested the effects of this
pathway on cultures of adult GRP78high and GRP78low
mammary epithelial populations. Consistent with its
greater enrichment for cells with a bipotent stem cell
phenotype (Figures 4E–4G; Figure S4B), theGRP78high pop-
ulation exhibits greatly enhanced potential for serial col-
ony formation relative to GRP78low cells, especially over
increasing serial passage number in Matrigel (Figure 4H;
Figure S4H). Furthermore, serial passage of GRP78high cells
is significantly enhanced by CRIPTO treatment (Figure 4H)
and, similar to what was observed with fMaSCs, serial
colony formation of adult GRP78high cells is also inhibited
by ALK4L75A-Fc treatment, suggesting that endogenous78low cells represented as in (C) (the data fit a single-hit model;
LK4L75A–Fc treatment when serially passaged in Matrigel culture.
hown, with SDs. Black bracket p < 0.05; red bracket p < 0.01.
ll-surface GRP78 in promoting mammary stem cell maintenance.
e, whereas loss of soluble CRIPTO signaling leaves cells vulnerable
such as bipotency (yellow cells) and self-renewal (circular arrow).
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these cells. By contrast, GRP78low cells are largely refractory
to treatment with CRIPTO or ALK4L75A-Fc (Figure 4H),
consistent with a requirement for surface GRP78 for
CRIPTO signaling (Kelber et al., 2009). Together, these
data support a role for soluble CRIPTO in maintaining
the stem cell phenotype of GRP78high mammary epithelial
cells.
The data are consistent with a model (Figure 4I) in
which surface GRP78 is a functional MaSC marker. In this
model, the most undifferentiated MaSC state depends on
endogenous CRIPTO signaling, because treatment with
ALK4L75A-Fc leads to loss of multipotency and eventual
rundown of self-renewal in serial passage. In addition,
a subset of cells, at least in the adult context, lacks endo-
genous CRIPTO but can respond to exogenous soluble
CRIPTOwith increased serial clonogenicity or self-renewal.
Thus, according to this model, CRIPTO treatment shifts
cells to a more primitive, stable, or competent stem cell
state while ALK4L75A-Fc treatment makes them susceptible
to commitment and differentiation.DISCUSSION
Extracellular signaling factors play critical roles in regu-
lating the balance between stem cell self-renewal and
differentiation (Jones and Wagers, 2008; Spradling et al.,
2001). In the present study, we identify CRIPTO as one
such factor that promotes multipotency and maintains
gland reconstitution potential of mammary stem/progeni-
tor cells ex vivo. We also show that the CRIPTO cell-surface
receptor GRP78 is required for MaSC activity and CRIPTO
responsiveness. Thus, CRIPTO andGRP78 are shared deter-
minants of both fetal and adult mammary stem/progenitor
cells pointing to a developmentally conserved role for the
CRIPTO/GRP78 pathway in maintenance of the MaSC
state.ALK4L75A-Fc Identifies Soluble CRIPTO as a MaSC
Factor
ALK4L75A-Fc selectively targets soluble CRIPTO and blocks
CRIPTO-induced PI3K/AKT signaling, indicating that
CRIPTO’s growth factor-like activity is essential for main-
tenance of MaSC properties in the contexts we analyzed.
Miharada et al. (2011) similarly showed that soluble
CRIPTO regulates hematopoietic stem cells (HSC) via the
PI3K/AKT pathway independent of SMAD2/3 signaling.
However, although our results uncover a critical role for
soluble CRIPTO growth-factor-like signaling in regulating
MaSC behavior, they do not exclude a role for CRIPTO
coreceptor function. Indeed, NODAL, which requires
CRIPTO or a related coreceptor, may act on fMaSCs during436 Stem Cell Reports j Vol. 2 j 427–439 j April 8, 2014 j ª2014 The Authordevelopment in vivo, because it is expressed in fetal mam-
mary stroma (Spike et al., 2012).
ALK4L75A-Fc treatment alone is sufficient to cause MaSC
differentiation and loss of self-renewal potential ex vivo,
suggesting that endogenously secreted CRIPTO sustains
the clonogenicity and multipotency of mammary epithe-
lial cells in maintenance media and in 3T3 fibroblast
cocultures. Consistent with this, CRIPTO treatment in-
hibits lineage commitment of cells in organoid culture
and increases their serial colony formation and transplan-
tation capacity. Therefore, CRIPTO acts as an extrinsic,
soluble regulator of MaSC function in vitro, raising the
possibility that it may function similarly as an auto-
crine/paracrine stem cell factor in vivo. In support of
such a role, we show that GRP78 is prominently expressed
throughout the ductal epithelium within the fetal mam-
mary rudiment while CRIPTO is concentrated near the
termini of the epithelial tree and the mesenchyme sur-
rounding these termini where stem cell activity may be
focused (Kenney et al., 2001). CRIPTO expression is low
in fMaSCs but higher in a variety of nonepithelial cells
of the mammary rudiment such as fat cells and macro-
phage/myeloid cells that could mark potential niche sour-
ces of secreted CRIPTO. Adipose tissue has been previ-
ously reported to express CRIPTO (Andersson et al.,
2008) and constitutes the natural environment for growth
and development of the mammary ductal epithelium
(Veltmaat et al., 2003). Myeloid cells, including macro-
phages, may also provide soluble CRIPTO for stem cell
regulation, because they comprise important niche com-
ponents in other systems and are required for effective
mammary reconstitution (Ehninger and Trumpp, 2011;
Gyorki et al., 2009).
Cell-Surface GRP78 Is a Developmentally Conserved
Marker of Fetal and Adult MaSCs
Our data identify cell-surface GRP78 as an enrichment
marker of mammary stem/progenitor cells. CRIPTO and
GRP78 are coexpressed in the adult mammary gland, and
cell-surface GRP78 correlates with the stem cell-surface
markers CD24 and CD49f (Stingl et al., 2006). Bipotent
stem/progenitor cells, though rare in the adult gland, are
relatively plentiful in the sorted GRP78high population.
GRP78high cells are also selectively responsive to CRIPTO
signaling, because CRIPTO and ALK4L75A-Fc had opposing
effects on their serial colony growth and neither treatment
significantly affected the GRP78low population. Interest-
ingly, the percentage of GRP78high cells is greater in the
fetal than in the adult mammary gland, in agreement
with the larger percentage of stem cells in the fetal mam-
mary gland than in the adult (Spike et al., 2012). However,
despite its ability to augment serial colony formation
in cultures derived from GRP78high adult cells, CRIPTOs
Stem Cell Reports
CRIPTO and GRP78 Regulate Mammary Stem Cellstreatment only has a modest effect on serial colony forma-
tion of fMaSCs in maintenance media. It is possible that
CRIPTO growth-factor-like signaling is maximally acti-
vated in newly isolated fetal, but not adult, stem cells.
This would explain the profound ability of the CRIPTO
antagonist ALK4L75A-Fc to inhibit fMaSC maintenance
despite the lack of a more profound effect of CRIPTO
treatment on these cells. This activity appears to be more
rapidly lost in stronger differentiation-promoting contexts,
unveiling a clear effect of exogenous CRIPTO in sustaining
a limited capacity for serial passage.
CRIPTO/GRP78 Signaling as a General Regulator
of the Stem Cell State
CRIPTO is an established regulator of embryonic stem cells
and induced pluripotent stem cells (Bianco et al., 2010),
whereas GRP78 is a necessary mediator of CRIPTO
signaling in human embryonic stem cells (Kelber et al.,
2009) and promotes survival and proliferation of the
murine inner cell mass cells that are precursors of murine
embryonic stem cells (Luo et al., 2006). In the adult,
GRP78 was recently reported to be essential for mainte-
nance of adult intestinal stem cells (Heijmans et al.,
2013) and conditional deletion of GRP78 in the hemato-
poietic system suppressed PI3K activity and decreased
HSC number (Wey et al., 2012a, 2012b). Furthermore,
CRIPTOwas shown to be a hypoxic niche-associated factor
that maintains the stem cell state and transplantability
of GRP78high HSCs cultured ex vivo (Miharada et al.,
2011). Although the mechanistic basis of CRIPTO/GRP78
signaling is still emerging, it has been shown that cell-
surface localization of GRP78 often correlates with its over-
all expression level and occurs under stress conditions in
which GRP78 is induced (Zhang et al., 2010). Therefore,
although the stem cell niche remains poorly defined in
the mammary gland, our results suggest that conditions
known to increase the levels of GRP78 and/or CRIPTO
such as hypoxia, nutrient deprivation, and endoplasmic
reticulum stress could impact stem cell maintenance,
expansion, and induction during normal mammary gland
development and in homeostasis. Similarly, other signals
from within the MaSC microenvironment likely intersect
with CRIPTO and GRP78. For instance, Wnt signaling
induces CRIPTO expression (Morkel et al., 2003) and has
been reported to promote MaSC self-renewal in vitro
(Zeng and Nusse, 2010).
Our recent demonstration that fMaSCs share a high
degree of similarity with certain human breast cancers
(Spike et al., 2012) is consistent with other evidence
suggesting that tumor initiation, aggressiveness, and
recurrence correlate with developmentally primitive states
that are associated with cellular plasticity and increased
stem cell disposition (Ben-Porath et al., 2008; MizunoStemet al., 2010; Spike and Wahl, 2011). The results presented
here show that CRIPTO/GRP78 signaling increases pro-
liferation and maintains the potency of MaSCs ex vivo
and raise the possibility that this pathwaymay be involved
in promoting stem cell-like states in cancer, especially
because expression of CRIPTO and GRP78 has been corre-
lated with breast cancer progression and decreased patient
survival (Dong et al., 2008; Gong et al., 2007; Lee, 2007).
The stress-related cues that increase the expression of
CRIPTO and GRP78 are prevalent in cancer and might
specifically promote stem cell properties via increased
CRIPTO/GRP78 signaling (Miharada et al., 2011; Zhang
et al., 2010). In this regard, the ALK4L75A-Fc CRIPTO antag-
onist described here would have potential as a stem cell-
directed cancer therapeutic.EXPERIMENTAL PROCEDURES
See Supplemental Information for additional details.
Reagents
ALK4L75A-Fc was produced in 293T cells and purified by sequential
protein-A and Flag affinity chromatography from conditioned
media. Recombinantmouse CRIPTO (R&D Systems) was iodinated
as previously described (Kelber et al., 2009). The following anti-
bodies were used: CRIPTO (Abcam), GRP78 (N-20, Santa Cruz
Biotechnology), KRT14 (AF-64, Covance), KRT8 (Troma-1, DSHB),
F4/80 (BM8, eBioscience), Ki67 (B56, BD). Polyclonal rabbit
antibodies directed against amino acids 19–39 of human GRP78
or amino acids 81–97 of mouse CRIPTO were produced in-house
(see Supplemental Information). The A3-luciferase reporter assay
has been described previously (Gray et al., 2003; Kelber et al.,
2008). GRP78 floxed mice were provided by Amy Lee (University
of Southern California).
Media
MCF10A media was composed of Dulbecco’s modified Eagle’s
medium/F12 with 5% horse serum, 10 mg/ml insulin, 20 ng/ml
epidermal growth factor, 100 ng/ml cholera toxin, 0.5 mg/ml
hydrocortisone, and 10 mg/ml ciprofloxacin. Maintenance media
was composed of MCF10A with 13 B27 supplement (Invitrogen).
Differentiation media was composed of Epicult-B mouse media
containing B supplement (Stem Cell Technologies), recombinant
human epidermal growth factor, recombinant human basic
fibroblast growth factor, and heparin, as previously described
(Spike et al., 2012), with ciprofloxacin 10 mg/ml.
Cell Preparation and Culture
All animal care and procedures were approved and monitored by
an Institutional Animal Care and Use Committee. MCF10A cells
were cultured free floating in CnT-27 media or immobilized in
MCF10A media with 2% Matrigel or 1% methylcellulose. Primary
cells were prepared, sorted, cultured, and stained as previously
described (Spike et al., 2012) using the indicatedmedia. 3T3 cocul-
tures were adapted from Makarem et al. (2013).Cell Reports j Vol. 2 j 427–439 j April 8, 2014 j ª2014 The Authors 437
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Proliferation in 2D was quantified on a Celigo microplate cyto-
meter (Cyntellect). Migrational dynamics were tracked using
time-lapse microscopy and Metamorph Imaging software on 2D
cultures on Matrigel. DNA content was measured by Hoechst
staining. mRNA abundance was measured using Superscript III
(Life Technologies) and TaqMan assays Mm03024051_g1 and
Mm01324427_m1 (Applied Biosciences). Mammary transplan-
tation analyses were conducted as previously described (Spike
et al., 2012). Organoid transplants used 20 organoids each by
dilution.Western blotting and quantitation of cell-surface proteins
by intact cell ELISA have also been previously described (Gray
et al., 2003; Kelber et al., 2008).Statistics
Data are presented as means and SDs with p values derived from
pairwise Student’s t tests, except where otherwise noted. ELDA
(http://bioinf.wehi.edu.au/software/elda) was used to estimate
stem cell frequencies.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and four movies and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2014.02.010.
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